Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
Safety, feasibility, and effectiveness of exercise interventions in patients with hematologic malignancy during chemotherapy: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Yuqin, Ren Yufang, Li Yuan, Yang Runyu, Cheng Yuyan, Chen Yulu, Deng Yan, Zheng Jingyu, Wang Yingli
Аннотация
PURPOSE: To evaluate the safety, feasibility, and effectiveness of exercise interventions aimed at improving the physical and/or mental health of patients with hematologic malignancies (HM) during chemotherapy.
METHODS: We systematically searched nine electronic databases for studies from their inception up to February 2024. The review process strictly adhered to the Cochrane guidelines and followed the PRISMA checklist for reporting systematic reviews. Sensitivity and subgroup analyses were conducted. When appropriate, we ran meta-regressions to locate the source of heterogeneity. Where statistical pooling was not appropriate, trials were instead summarized in narrative form.
RESULTS: Thirty-three studies were included in this systematic review, of which 19 were included in the meta-analysis. Five studies reported 19 exercise-related no serious adverse events. Twenty-eight studies reported that exercise interventions were feasible or had high participation rates. The results revealed significant improvements in physical fitness parameters among the exercise intervention group compared to the control group. Specifically, we observed substantial enhancements in the timed walking distance (TMD) (SMD = 0.696; 95%CI, [0.455,0.988]; p < 0.001)), timed up and go test (TUG) (SMD = -0.570; 95%CI, [-0.867, -0.273]; p < 0.001), peak oxygen consumption (VO2 peak) (SMD = 0.532; 95%CI, [0.261, 0.804]; p < 0.001), lower muscle strength (SMD = 0.346; 95%CI, [0.018,0.674]; p = 0.039) and upper muscle strength. Moreover, our findings demonstrated that exercise intervention significantly reduced depression scores (SMD = -0.692; 95%CI, [-0.631,-0.157]; p = 0.001) compared to usual care. However, non significant effects were found for anxiety and quality of life (QOL). The narrative summary of evidence for fatigue showed uncertain intervention effects, and our meta-regression analysis did not identify any covariates significantly associated with fatigue outcomes.
CONCLUSION: Generally, the exercise intervention appear safe and feasible, and can improve physical fitness and depression in adult patients with HM during chemotherapy. Currently, there is inconclusive evidence regarding QOL, fatigue and anxiety. Further trials with larger sample size and longer follow-up periods are warranted to evaluate the effects of exercise interventions for patients with HM.
METHODS: We systematically searched nine electronic databases for studies from their inception up to February 2024. The review process strictly adhered to the Cochrane guidelines and followed the PRISMA checklist for reporting systematic reviews. Sensitivity and subgroup analyses were conducted. When appropriate, we ran meta-regressions to locate the source of heterogeneity. Where statistical pooling was not appropriate, trials were instead summarized in narrative form.
RESULTS: Thirty-three studies were included in this systematic review, of which 19 were included in the meta-analysis. Five studies reported 19 exercise-related no serious adverse events. Twenty-eight studies reported that exercise interventions were feasible or had high participation rates. The results revealed significant improvements in physical fitness parameters among the exercise intervention group compared to the control group. Specifically, we observed substantial enhancements in the timed walking distance (TMD) (SMD = 0.696; 95%CI, [0.455,0.988]; p < 0.001)), timed up and go test (TUG) (SMD = -0.570; 95%CI, [-0.867, -0.273]; p < 0.001), peak oxygen consumption (VO2 peak) (SMD = 0.532; 95%CI, [0.261, 0.804]; p < 0.001), lower muscle strength (SMD = 0.346; 95%CI, [0.018,0.674]; p = 0.039) and upper muscle strength. Moreover, our findings demonstrated that exercise intervention significantly reduced depression scores (SMD = -0.692; 95%CI, [-0.631,-0.157]; p = 0.001) compared to usual care. However, non significant effects were found for anxiety and quality of life (QOL). The narrative summary of evidence for fatigue showed uncertain intervention effects, and our meta-regression analysis did not identify any covariates significantly associated with fatigue outcomes.
CONCLUSION: Generally, the exercise intervention appear safe and feasible, and can improve physical fitness and depression in adult patients with HM during chemotherapy. Currently, there is inconclusive evidence regarding QOL, fatigue and anxiety. Further trials with larger sample size and longer follow-up periods are warranted to evaluate the effects of exercise interventions for patients with HM.